Alfaro Carlos, Echeveste Jose I, Rodriguez-Ruiz Maria E, Solorzano Jose L, Perez-Gracia Jose L, Idoate Miguel A, Lopez-Picazo Jose M, Sanchez-Paulete Alfonso R, Labiano Sara, Rouzaut Ana, Oñate Carmen, Aznar Angela, Lozano Maria D, Melero Ignacio
Division of Gene Therapy and Hepatology; Centre for Applied Medical Research ; Pamplona, Spain ; Oncology Department; University Clinic of Navarra ; Pamplona, Spain.
Pathology Department; University Clinic of Navarra ; Pamplona, Spain.
Oncoimmunology. 2015 May 29;4(12):e1054597. doi: 10.1080/2162402X.2015.1054597. eCollection 2015 Dec.
CD137 (4-1BB) is a surface protein initially discovered to mark activated T lymphocytes. However, its broader expression pattern also encompasses activated NK cells, B cells and myeloid cells, including mature dendritic cells. In this study, we have immunostained for CD137 on paraffin-embedded lymphoid tissues including tonsils, lymph nodes, ectopic tertiary lymphoid tissue in Hashimoto thyroiditis and cancer. Surprisingly, immunostaining mainly decorated intrafollicular lymphocytes in the tissues analyzed, with only scattered staining in interfollicular areas. Moreover, pathologic lymphoid follicles in follicular lymphoma and tertiary lymphoid tissue associated with non-small cell lung cancer showed a similar pattern of immunostaining. Multispectral fluorescence cytometry demonstrated that CD137 expression was restricted to CD4 CXCR5 follicular T helper lymphocytes (T cells) in tonsils and lymph nodes. Short-term culture of lymph node cell suspensions in the presence of either an agonistic anti-CD137 monoclonal antibody (mAb) or CD137-ligand stimulated the functional upregulation of T cells in 3 out of 6 cases, as indicated by CD40L surface expression and cytokine production. As a consequence, immunostimulatory monoclonal antibodies targeting CD137 (such as urelumab and PF-05082566) should be expected to primarily act on this lymphocyte subset, thus modifying ongoing humoral immune responses in patients with autoimmune disease and cancer.
CD137(4-1BB)是一种最初被发现可标记活化T淋巴细胞的表面蛋白。然而,其更广泛的表达模式还包括活化的自然杀伤细胞、B细胞和髓系细胞,包括成熟树突状细胞。在本研究中,我们对石蜡包埋的淋巴组织(包括扁桃体、淋巴结、桥本甲状腺炎中的异位三级淋巴组织和癌症组织)进行了CD137免疫染色。令人惊讶的是,免疫染色主要出现在所分析组织的滤泡内淋巴细胞上,滤泡间区域仅有散在染色。此外,滤泡性淋巴瘤中的病理性淋巴滤泡和与非小细胞肺癌相关的三级淋巴组织显示出类似的免疫染色模式。多光谱荧光细胞术表明,CD137表达仅限于扁桃体和淋巴结中的CD4 CXCR5滤泡辅助性T淋巴细胞(T细胞)。在存在激动性抗CD137单克隆抗体(mAb)或CD137配体的情况下,对淋巴结细胞悬液进行短期培养,6例中有3例显示T细胞功能上调,表现为CD40L表面表达和细胞因子产生。因此,可以预期靶向CD137的免疫刺激单克隆抗体(如乌瑞珠单抗和PF-05082566)主要作用于该淋巴细胞亚群,从而改变自身免疫性疾病和癌症患者正在进行的体液免疫反应。